UOC
BCRX icon

UBS O'Connor’s BioCryst Pharmaceuticals BCRX Stock Holding History

UBS O'Connor’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-32,630
Closed -$166K – 551
2024
Q1 		$166K Sell
32,630
-27,529
-46% -$155K ﹤0.01% 408
2023
Q4 		$360K Sell
60,159
-181,661
-75% -$1.05M 0.01% 379
2023
Q3 		$1.71M Buy
241,820
+9,357
+4% +$67.2K 0.03% 263
2023
Q2 		$1.64M Buy
232,463
+6,699
+3% +$53.8K 0.03% 328
2023
Q1 		$1.88M Sell
225,764
-19,249
-8% -$185K 0.04% 332
2022
Q4 		$2.81M Buy
245,013
+28,686
+13% +$358K 0.05% 331
2022
Q3 		$2.73M Sell
216,327
-20,000
-8% -$257K 0.03% 467
2022
Q2 		$2.5M Buy
236,327
+192,527
+440% +$1.99M 0.03% 603
2022
Q1 		$712K Buy
+43,800
New +$703K 0.01% 728

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

UBS O'Connor's BCRX Position: Q2 2024 in Review

UBS O'Connor sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2024, closing a stake of 32,630 shares — an estimated $166K sold.

UBS O'Connor first reported a position in BCRX in Q1 2022 and held it in 9 quarters. The position peaked at $2.81M in Q4 2022. 242 funds tracked by Wall St. Rank hold BCRX as of Q2 2024.

  • UBS O'Connor reported no remaining BioCryst Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • UBS O'Connor sold 32,630 BioCryst Pharmaceuticals shares in Q2 2024, an estimated $166K.
  • UBS O'Connor first reported a position in BioCryst Pharmaceuticals in Q1 2022 and held it in 9 quarters.
  • UBS O'Connor's BioCryst Pharmaceuticals position peaked at $2.81M in Q4 2022.
  • 242 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2024.

Based on UBS O'Connor's 13F filing for Q2 2024, filed 14 Aug 2024.